scientific goals of the project), and to ensure the recruitment and retention of human subjects.

12. Human Subjects—The quality of procedures for the protection of human subjects, and plans for documenting all procedures for compliance with applicable published regulations.

The secondary review will be conducted by a panel of Senior Federal Officials based on the ranked proposals to assure maximal impact and balance of proposed research. The factors to be considered will include:

1. The results of the primary review including the proposal's priority score as the primary factor in the selection process.

2. The match between the proposal and the program announcement and programmatic interests.

3. The relevance and balance of proposed research relative to CDC programs and priorities

programs and priorities.
4. The significance of the proposed activities in relation to the priorities and objectives stated in "Health People 2000"

5. Geographic balance and budgetary considerations.

I. Other Requirements

Technical Reporting Requirements
Provide CDC with an original plus

two copies of 1. Annual progress reports,

2. Financial status report, no more that 90 days after the end of the budget period, and

3. Final financial report and performance report, no more than 90 days after the end of the project period.

Send all reports to the Grants Management Specialist listed in Section K "Where to Obtain Additional Information".

The following additional requirements are applicable to this program. For a complete description of each, see Addendum I in the application package.

AR-1—Human Subjects Requirements AR-2—Requirements for Inclusion of Women and Racial and Ethnic Minorities in Research

AR-3—Public Health System Reporting Requirements

AR-10—Smoke-Free Workplace Requirements

AR-11—Healthy People 2000 AR-12—Lobbying Restrictions

J. Authority and Catalog of Federal Domestic Assistance Number

This program is authorized under sections 301 and 317 [42U.S.C.241 and 247b] of the Public Health Service Act, as amended. The catalog of Federal Domestic Assistance number is 93.283.

K. Where To Obtain Additional Information

This and other CDC announcements may be downloaded through the CDC homepage on the Internet at http:// www.cdc.gov. Please refer to Program Announcement Number 99117 when requesting information. To receive additional written information and to request an application kit, call 1-888-GRANTS4 (1-888-472-6874). You will be asked to leave your name and address and will be instructed to identify the Announcement number of interest. If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained

Mattie Jackson, Grant Management Specialist, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 2920 Brandywine Road, Room 3000, Atlanta, Georgia 30341–4146, Telephone: (770) 488– 2718, Internet address: mij3@cdc.gov

For program technical assistance contact: Marta Gwinn, M.D., M.P.H., Office of Genetics and Disease Prevention, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, NE, Mailstop K–28, Atlanta, Georgia 30341–3724, telephone (770) 488–3235, Internet address: mlg1@cdc.gov

Dated: April 28, 1999.

John L. Williams,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99–11097 Filed 5–3–99; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Grants for Radiation Studies and Research

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Grants for Radiation Studies and Research, in response to Program Announcement 99020.

Times and Dates: 8 a.m.—9 a.m., May 19, 1999 (Open); 9 a.m.—6 p.m., May 19, 1999 (Closed); 8 a.m.—5 p.m., May 20, 1999 (Closed).

Place: Centers for Disease Control and Prevention, Chamblee Campus, Building 101, (Room 1301B on May 19; Room 3002 on May 20), 4770 Buford Highway, NE, Atlanta, GA.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92–463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement 99020.

Contact Person For More Information: C.M. Wood, CDC, NCEH, Chamblee Campus, Building 101, 4770 Buford Highway, NE, Atlanta, GA., phone 770/488–7642.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: April 28, 1999.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention CDC.

[FR Doc. 99–11096 Filed 5–3–99; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Assessment of Preclinical Reproductive Toxicity Data; Public Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting.

SUMMARY: The Food and Drug Administration (FDA) is announcing a public meeting to discuss an approach for the integrative assessment of preclinical reproductive toxicity findings and other information for pharmaceuticals. The purpose of the meeting is to provide information on the agency's approach, using several pharmaceutical data sets, and to invite members of the public to provide comments on the utility of the approach. The agency intends to consider feedback from the meeting in the development of guidance for integrative assessments of pharmaceutical reproductive risk.

DATES: The public meeting will be held on June 24, 1999, from 9 a.m. to 4 p.m.

Submit registration information by June 11, 1999.

ADDRESSES: The public meeting will be held in the Center for Drug Evaluation and Research Advisory Committee Conference Room, 5630 Fishers Lane, rm. 1066, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT:

Adele S. Seifried, Center for Drug Evaluation and Research (HFD–024), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–5482.

SUPPLEMENTARY INFORMATION:

Registration. Although there is no fee, preregistration by June 11, 1999, is required for all attendees at this meeting. Participation is limited to the first 75 registrants outside FDA and is also restricted within FDA due to limited meeting space. Persons interested in attending the meeting should register via e-mail to 'wedge@cder.fda.gov'' using the registration form on the Center for Drug Evaluation and Research home page "http://www.fda.gov/cder" or, if e-mail is not available, fax their registration information (including name, affiliation, address, telephone, fax number, and email address) to 301-827-6801, ATTN: Kimberly L. Topper. Interested persons may also register by mailing the registration information to the contact person identified previously.

Building Location and Admittance. The building at 5630 Fishers Lane is the former Social Services Building located next to the Parklawn Building. Please use the lower entrance, which faces Parklawn Dr. Visitor badges for nonagency participants will be held at the guard station at the entrance to the building. Participants will need picture identification to pick up their badge.

Parking. There is no public parking at the building at 5630 Fishers Lane. A public parking lot (for a fee) is located on Fishers Lane across from the Parklawn building, and additional public parking (for a fee) is available at the Twinbrook Metro station located several blocks to the west.

Agenda. An agenda for the public meeting will be available 2 weeks before the meeting, via the Internet using the World Wide Web (WWW). Connect to the CDER home page at "http://www.fda.gov/cder" and go to the "What's Happening" section.

Dated: April 28, 1999.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 99–11122 Filed 5–3–99; 8:45 am] BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration [Document Identifier: HCFA-R-0254]

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Health Care Financing Administration, HHS.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Type of Information Collection Request: Reinstatement, without change, or a previously approved collection for which approval has expired.

Title of Information Collection: National Medicare Education Program (NMEP) Community Survey of Medicare Beneficiaries.

Form No.: HCFA-R-0254 (OMB# 0938-0738).

Use: A survey of Medicare beneficiaries in six communities will be conducted to monitor the NMEP implementation. Beneficiaries in these same communities were interviewed in September 1998 and February 1999. This approach will gather information on changes in: awareness of Medicare+Choice expansions and options; knowledge about Medicare and the Medicare+Choice options; where beneficiaries go to find more information; and whether they are aware of the many information resources available to them; and satisfaction with their information/ knowledge.

Frequency: Annually.
Affected Public: Individuals or
Households.

Number of Respondents: 2,400. Total Annual Responses: 2,400. Total Annual Hours: 600.

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access HCFA's Web Site address at http://www.hcfa.gov/ regs/prdact95.htm, or E-mail your request, including your address, phone number, OMB number, and HCFA document identifier, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786-1326. Written comments and recommendations for the proposed information collections must be mailed within 60 days of this notice directly to the HCFA Paperwork Clearance Officer designated at the following address: HCFA, Office of Information Services,

Security and Standards Group, Division of HCFA Enterprise Standards, Attention: Louis Blank, Room N2–14–26, 7500 Security Boulevard, Baltimore, Maryland 21244–1850

Dated: April 26, 1999.

John P. Burke III,

HCFA Reports Clearance Officer, HCFA Office of Information Services, Security and Standards Group, Division of HCFA Enterprise Standards.

[FR Doc. 99–11150 Filed 5–3–99; 8:45 am] BILLING CODE 4120–03–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

[Document Identifier: HCFA-R-138]

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Health Care Financing Administration, HHS.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to